Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Zogenix Inc. : Trading of Zogenix Common Stock Halted

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/07/2012 | 02:00pm CEST

FDA Advisory Committee Reviewing Zohydro™ ER New Drug Application

Zogenix to Host Conference Call at 6:30 pm ET Today

SAN DIEGO, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced that NASDAQ halted trading of the company's common stock on December 7, 2012. The U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) is meeting today to review the Company's New Drug Application (NDA) for Zohydro™ ER (hydrocodone bitartrate extended-release capsules).

Conference Call & Webcast

Zogenix will host a conference call to discuss the outcome of the AADPAC meeting today, Friday, December 7, 2012 at 6:30 p.m. ET (3:30 p.m. PT). To participate, please dial (800) 299-9086 (U.S.) or (617) 786-2903 (International); participant passcode: 21970283. To access the live webcast please visit the Zogenix Investor Relations website at http://ir.zogenix.com.  

The conference call will be hosted by Chief Executive Officer Roger L. Hawley and President and Chief Operating Officer Stephen J. Farr, Ph.D.

A replay of the conference call will be available beginning December 7, 2012 at 8:30 p.m. ET (5:30 p.m. PT) until December 14, 2012, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 27116437. A replay of the webcast will also be accessible on the Investor Relations website for one month, through January 10, 2013.

About Anesthetic and Analgesic Drug Products Advisory Committee

The AADPAC reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human anesthetic and analgesic drug products and makes appropriate recommendations to the Commissioner of Food and Drugs. The AADPAC provides FDA with independent expert advice and recommendations, however, the final decision regarding approval is made by FDA.

About Zogenix

Zogenix, Inc., with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, ZohydroTM ER (hydrocodone bitartrate) is an oral, novel extended-release formulation of various strengths of hydrocodone without acetaminophen intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. Zogenix's second DosePro investigational product candidate, ReldayTM, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER and an Investigational New Drug Application for Relday. The FDA assigned a PDUFA target action date of March 1, 2013 for the Zohydro ER NDA.

For additional information, please visit www.zogenix.com.

SUMAVEL ®, DosePro ®, ReldayTM and ZohydroTM ER are trademarks of Zogenix, Inc.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Emily Poe | WCG
         212.301.7183 | epoe@wcgworld.com
Zogenix
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
Date Title
12:19a ICAO INTERNATIONAL CIVIL AVIATION ORGANIZATION : Republic of Korea and ICAO agree to new cooperation on aviation safety and planned aviation museum
12:04a R. REX PARRIS : SoCal Gas -- Trust us, there was only one bad storage well at Aliso Canyon
12:02a MANCHESTER UNITED : Mauricio Pochettino can press Tottenham claim by beating Manchester City
12:01a Zonar Ushers in a New Era of Fleet Management Technology with Zonar Connect
10/01 TELEPHONE & DATA : and data transmission services
10/01 BOUYGUES : Legal assistance in favor of the A400M program
10/01 BOUYGUES : Forecasting and Strategic Study No. 2016-04 Entitled Study on the links entre universities
10/01 BOUYGUES : Realisation and maintenance third unified interface input source connected to the Web systems of information
10/01 CENTRAL FINANCE : Geographic information systems (GIS or equivalent)
10/01 For Buffers, Test Kits, Reagents, Qiagen
Latest news
Advertisement
Hot News 
-13.25%COGNIZANT TECHNOLOGY : Investigating Indian Payments
2.60%MCCORMICK MPANY INCORPORATED : Boosts Full-Year Outlook
3.40%Costco quarterly profit beats on lower fees to Visa
5.41%Savannah Resources 1st Half Net Loss Narrows; Extends JV Deadline
-2.85%H & M HENNES & MAURITZ : &M 3Q Net-Profit Falls 9% on Quarter
Most Read News
06:02p MANCHESTER UNITED : Mauricio Pochettino can press Tottenham claim by beating Manchester City
02:48aDJCBS : Viacom, CBS Move to Explore Merger -- WSJ
02:49aDJAT&T : to Stop Collecting Customers' Internet Visits -- WSJ
09/30 VOLKSWAGEN : will pay $1.21 billion to settle U.S. dealer claims
09:48aDJDEUTSCHE BANK : Current and Former MPS, Deutsche Bank, Nomura Executives Charged in Italy -- 2nd Update
Most recommended articles
09/26Predicting the U.S. Elections With The WMA Trump/Clinton Barometer
03:53p DEUTSCHE BANK : executives heading to U.S. in coming days - FAZ
02:23p EXCLUSIVE : EU wants Google to stop anti-competitive Android practices, fine expected
12:37p COMMERZBANK : German bank regulator warns of negative perception spiral
09:18a Milan court orders trial over Monte dei Paschi trades - legal sources